Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:624-630
doi: 10.1161/01.STR.0000250166.06949.95
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Onalan, O.
Right arrow Articles by Crystal, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onalan, O.
Right arrow Articles by Crystal, E.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Atrial Fibrillation
*Stroke
Related Collections
Right arrow Embolic stroke
Right arrow Primary and Secondary Stroke Prevention
Right arrow Anticoagulants
Right arrow Other Stroke Treatment - Medical
Right arrow Other Stroke Treatment - Surgical

(Stroke. 2007;38:624.)
© 2007 American Heart Association, Inc.


Novel Approaches to Stroke Prevention in Atrial Fibrillation: Introduction

Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation

Orhan Onalan, MD Eugene Crystal, MD

From Arrhythmia Services, Division of Cardiology, Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada.

Correspondence to Eugene Crystal MD, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Suite D-377, Toronto, ON M4N 3M5, Canada. E-mail: eugene.crystal{at}sunnybrook.ca

Abstract

The efficacy of oral anticoagulation (OAC) for stroke prevention in patients with nonrheumatic atrial fibrillation (AF) has clearly been established. However, a substantial number of patients with AF who are at high risk for thromboembolic events are not candidates for long-term OAC. The left atrial appendix (LAA) is the most common place of thrombosis in patients with AF, and it can easily be excluded from the systemic circulation at the time of cardiac surgery by excision, ligation, suturing, or stapling. Currently, removal of the LAA at the time of mitral valve surgery is recommended to reduce future stroke risk. The ongoing LAA Occlusion Study (LAAOS) is evaluating the efficacy of the routine LAA occlusion in patients undergoing elective coronary artery bypass graft surgery. Recently, two devices specifically designed for percutaneous transcatheter LAA occlusion have been introduced: the Percutaneous LAA Transcatheter Occlusion (PLAATO; Appriva Medical Inc) and WATCHMAN LAA system (Atritech, Inc). More than 200 PLAATO devices were implanted worldwide in patients with nonrheumatic AF who were at high risk for ischemic stroke and not candidates for long-term OAC. In a follow-up time of 258 patient-years, an estimated 61% reduction in stroke risk was achieved with PLAATO procedure. The WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) study was designed to demonstrate the safety and efficacy of the WATCHMAN device in patients with nonvalvular AF who are eligible for long-term OAC. The trial is assessing whether the treatment arm (WATCHMAN device) is noninferior to the control arm (warfarin). Although present results suggest that LAA occlusion may reduce the long-term stroke risk, available data are still very limited. At present, percutaneous LAA occlusion may be an acceptable option in selected high-risk patients with AF who are not candidates for OAC. The current understanding of LAA exclusion for the prevention of stroke in patients with nonrheumatic AF is the major focus of this review.


Key Words: atrial fibrillation • left atrial appendage • stroke




This article has been cited by other articles:


Home page
CirculationHome page
D. R. Holmes Jr and R. S. Schwartz
Left Atrial Appendage Occlusion Eliminates the Need for Warfarin
Circulation, November 10, 2009; 120(19): 1919 - 1926.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin
Prevention of stroke in patients with atrial fibrillation: current strategies and future directions
Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H4 - H10.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
N U Weir
An update on cardioembolic stroke
Postgrad. Med. J., March 1, 2008; 84(989): 133 - 142.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. B. Singhal and E. H. Lo
Advances in Emerging Nondrug Therapies for Acute Stroke 2007
Stroke, February 1, 2008; 39(2): 289 - 291.
[Full Text] [PDF]


Home page
StrokeHome page
C. Stollberger, J. Finsterer, and B. Schneider
Arguments Against Left Atrial Appendage Occlusion for Stroke Prevention
Stroke, September 1, 2007; 38(9): e77 - e77.
[Full Text] [PDF]